{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:44:54Z","timestamp":1787633094183,"version":"build-2736575974"},"reference-count":182,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuromuscular Diseases"],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Spinal muscular atrophy (SMA) is caused by bi-allelic, recessive mutations of the survival motor neuron 1 (\n                      <jats:italic toggle=\"yes\">SMN1<\/jats:italic>\n                      ) gene and reduced expression levels of the survival motor neuron (SMN) protein. Degeneration of alpha motor neurons in the spinal cord causes progressive skeletal muscle weakness. The wide range of disease severities, variable rates of decline, and heterogenous clinical responses to approved disease-modifying treatment remain poorly understood and limit the ability to optimize treatment for patients. Validation of a reliable biomarker(s) with the potential to support early diagnosis, inform disease prognosis and therapeutic suitability, and\/or confirm response to treatment(s) represents a significant unmet need in SMA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The SMA Multidisciplinary Biomarkers Working Group, comprising 11 experts in a variety of relevant fields, sought to determine the most promising candidate biomarker currently available, determine key knowledge gaps, and recommend next steps toward validating that biomarker for SMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The Working Group engaged in a modified Delphi process to answer questions about candidate SMA biomarkers. Members participated in six rounds of reiterative surveys that were designed to build upon previous discussions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The Working Group reached a consensus that neurofilament (NF) is the candidate biomarker best poised for further development. Several important knowledge gaps were identified, and the next steps toward filling these gaps were proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>NF is a promising SMA biomarker with the potential for prognostic, predictive, and pharmacodynamic capabilities. The Working Group has identified needed information to continue efforts toward the validation of NF as a biomarker for SMA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jnd-230054","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T11:42:54Z","timestamp":1689334974000},"page":"937-954","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Identifying Biomarkers of Spinal Muscular Atrophy for Further Development"],"prefix":"10.1177","volume":"10","author":[{"given":"Jacqueline","family":"Glascock","sequence":"first","affiliation":[{"name":"Cure SMA","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[{"name":"Boston Children\u2019s Hospital\/Harvard Medical School","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Crawford","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Departments of Neurology and Neuroscience, Department of Neurology and Pediatrics","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte J.","family":"Sumner","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine Departments of Neurology and Neuroscience, Department of Neurology and Pediatrics","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center","place":["USA"]},{"name":"The Ohio State University Wexner Medical Center","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"DiDonato","sequence":"additional","affiliation":[{"name":"Ann & Robert H. Lurie Children\u2019s Hospital of Chicago","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakri","family":"Elsheikh","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Howell","sequence":"additional","affiliation":[{"name":"Spinal Muscular Atrophy Foundation","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wildon","family":"Farwell","sequence":"additional","affiliation":[{"name":"Biogen","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Valente","sequence":"additional","affiliation":[{"name":"Biogen","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Petrillo","sequence":"additional","affiliation":[{"name":"Biogen","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Tingey","sequence":"additional","affiliation":[{"name":"Cure SMA","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Jarecki","sequence":"additional","affiliation":[{"name":"Cure SMA","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25101"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.134"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13091657"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2147\/TACG.S239603"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-102319-103602"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01262-08"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314292"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-006-0156-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.01.003"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0811-4"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00125817-200201000-00004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20473"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21350"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-019-01983-0"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-71"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2849-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2005.12.001"},{"issue":"5","key":"e_1_3_3_21_2","first-page":"518","article-title":"Natural history in proximal spinal muscular atrophy","volume":"52","author":"Zerres K","year":"1995","unstructured":"ZerresK, Rudnik-SchonebornS Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518\u201323.","journal-title":"Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0929-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51281"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02455-x"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01356-1"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02227-7"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000741"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.373"},{"issue":"8","key":"e_1_3_3_29_2","first-page":"703","article-title":"An observational study of functional abilities in infants, children, and adults with type 1 sma","volume":"91","author":"Pane M","year":"2018","unstructured":"PaneM, PalermoC, MessinaS, SansoneVA, BrunoC, CatterucciaM, et al. An observational study of functional abilities in infants, children, and adults with type 1 sma. Neurology.e696-e. 2018;91(8):703.","journal-title":"Neurology.e696-e"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305673"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180304"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190468"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190424"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070119-115459"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030417"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00413-4"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1941310"},{"issue":"72","key":"e_1_3_3_38_2","first-page":"18","article-title":"Antisense oligonucleotides delivered to the mouse cns ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini MA","year":"2011","unstructured":"PassiniMA, BuJ, RichardsAM, KinnecomC, SardiSP, StanekLM, et al. Antisense oligonucleotides delivered to the mouse cns ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med.72ra. 2011;3(72):18.","journal-title":"Sci Transl Med.72ra"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41615"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01559-4"},{"key":"e_1_3_3_42_2","unstructured":"Spinraza prescribing information. Cambridge: Biogen; 2016."},{"key":"e_1_3_3_43_2","unstructured":"Evrysdi prescribing information. San Francisco: Genentech; 2020."},{"key":"e_1_3_3_44_2","unstructured":"Zolgensma prescribing information. Bannockburn: AveXis Inc.; 2019."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2066471"},{"issue":"21","key":"e_1_3_3_46_2","first-page":"506","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"Darras BT","unstructured":"DarrasBT, ChiribogaCA, IannacconeST, SwobodaKJ, MontesJ, MignonL, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies. Neurology.e-e. 2492;92(21):506.","journal-title":"Neurology.e-e"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31408-8"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00100-0"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180315"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02547-8"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190416"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30037-5"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.12.006"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190403"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00001-6"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.1272"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00251-9"},{"key":"e_1_3_3_61_2","article-title":"Onasemnogene abeparvovec in type 1spinal muscular atrophy: A systematic review and meta-analysis","author":"Pascual-Morena C","year":"2022","unstructured":"Pascual-MorenaC, Cavero-RedondoI, Lucer\u00f3n-Lucas-TorresM, Mart\u00ednez-Garc\u00edaI, Rodr\u00edguez-Guti\u00e9rrezE, Mart\u00ednez-Vizca\u00ednoV Onasemnogene abeparvovec in type 1spinal muscular atrophy: A systematic review and meta-analysis. HumGene Ther. 2022.","journal-title":"HumGene Ther"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01866-4"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01867-3"},{"key":"e_1_3_3_64_2","first-page":"2021","article-title":"Risdiplam in type 1 spinal muscular atrophy","author":"Baranello G","unstructured":"BaranelloG, DarrasBT, DayJW, DeconinckN, KleinA, MassonR, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 2021.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102047"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00339-8"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13786"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00367-7"},{"key":"e_1_3_3_69_2","unstructured":"Cure SMA. Clinical trials 2022. Available from: https:\/\/www.curesma.org\/sma-care-center-network\/."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001102"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03671-x"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04408-w"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2020.11.009"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.07.014"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27034"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.283"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167087"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13101911"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.011"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26995"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230012"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033572"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1086\/515465"},{"issue":"9","key":"e_1_3_3_84_2","first-page":"640","article-title":"The c","volume":"47","author":"Bernal S","year":"2010","unstructured":"BernalS, Al\u00edasL, Barcel\u00f3MJ, Also-RalloE, Mart\u00ednez-Hern\u00e1ndezR, G\u00e1mezJ, et al. The c. 859g>cvariant in the smn2 gene is associated with types ii and iii sma andoriginates from a common ancestor. J Med Genet. 2010;47(9):640\u20132.","journal-title":"859g>cvariant in the smn2 gene is associated with types ii and iii sma andoriginates from a common ancestor. J Med Genet"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2013.111"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1155085"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2017.01.005"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.239"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds540"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132364"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.47"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8020021"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13450"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15382"},{"issue":"1","key":"e_1_3_3_95_2","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010170","article-title":"Identification of novel csf-derived mirnas in treated paediatric onset spinal muscular atrophy: An exploratory study","volume":"15","author":"D\u2019Silva AM","year":"2023","unstructured":"D\u2019SilvaAM, KariyawasamD, VenkatP, MayohC, FarrarMA Identification of novel csf-derived mirnas in treated paediatric onset spinal muscular atrophy: An exploratory study. Pharmaceutics. 2023; 15(1).","journal-title":"Pharmaceutics"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn357"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.B1500072"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121964"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.146109"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/ahg.12288"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-020-00628-z"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15198"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.11.033"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141020427"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4695(199604)29:4<503::AID-NEU7>3.0.CO;2-C"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2018-105482"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.779"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1136\/vr.134.10.232"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14939"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101524"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51645"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16802"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51449"},{"key":"e_1_3_3_115_2","first-page":"2022","article-title":"Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy","author":"Orbach R","unstructured":"OrbachR, SagiL, SadotE, TokatlyLatzer I, ShtamlerA, ZisbergT, et al. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy. Muscle Nerve 2022.","journal-title":"Muscle Nerve"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210735"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51336"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320033"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09389-8"},{"key":"e_1_3_3_120_2","article-title":"Total tau incerebrospinal fluid detects treatment responders among spinalmuscular atrophy types 1-3 patients treated with nusinersen","author":"\u0160imi\u0107 G","year":"2022","unstructured":"\u0160imi\u0107G, Vuki\u0107V, Babi\u0107M, Banovi\u0107M, Bere\u010di\u0107 I, \u0160pani\u0107 E, et al. Total tau incerebrospinal fluid detects treatment responders among spinalmuscular atrophy types 1-3 patients treated with nusinersen. CNSNeuroscience & Therapeutics. 2022.","journal-title":"CNSNeuroscience & Therapeutics"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-190416"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01071-0"},{"issue":"9","key":"e_1_3_3_123_2","first-page":"31","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves CRR","year":"2020","unstructured":"AlvesCRR, ZhangR, JohnstoneAJ, GarnerR, NwePH, SiranosianJJ, et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology.e921-e. 2020;94(9):31.","journal-title":"Neurology.e921-e"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51340"},{"issue":"11","key":"e_1_3_3_125_2","first-page":"11","article-title":"Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy","volume":"92","author":"Lombardi V","unstructured":"LombardiV, QuerinG, ZiffOJ, ZampedriL, MartinelliI, HellerC, et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology.e-e. 1205;92(11):11.","journal-title":"Neurology.e-e"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10048"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23233"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111428"},{"key":"e_1_3_3_129_2","article-title":"Mri correlates of motoneuron loss in sma","author":"Sprenger-Svacina A","year":"2022","unstructured":"Sprenger-SvacinaA, HaenschJ, WeissK, GrosseHokamp N, MaintzD, SchlamannM, et al. Mri correlates of motoneuron loss in sma. J Neurol. 2022.","journal-title":"J Neurol"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25385"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00242-2"},{"issue":"2","key":"e_1_3_3_132_2","first-page":"76","article-title":"Muscle quantitative mri in adult sma patients on nusinersen treatment: A longitudinal study","volume":"41","author":"Gallone A","year":"2022","unstructured":"GalloneA, MazziF, BonannoS, ZaninR, MoscatelliM, AquinoD, et al. Muscle quantitative mri in adult sma patients on nusinersen treatment: A longitudinal study. Acta Myol. 2022;41(2):76\u201383.","journal-title":"Acta Myol"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14587"},{"key":"e_1_3_3_134_2","article-title":"Muscle impairment in mri affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3 A retrospective cohort study","author":"Shimizu-Motohashi Y","year":"2022","unstructured":"Shimizu-MotohashiY, ChibaE, MizunoK, YajimaH, IshiyamaA, TakeshitaE, et al. Muscle impairment in mri affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3 A retrospective cohort study. Brain Dev. 2022.","journal-title":"Brain Dev"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.23"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23967"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21838"},{"key":"e_1_3_3_138_2","article-title":"Emerging therapies and challenges in spinal muscular atrophy","author":"Farrar MA","year":"2016","unstructured":"FarrarMA, ParkSB, VucicS, CareyKA, TurnerBJ, GillingwaterTH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2016.","journal-title":"Ann Neurol"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24332"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15117"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1177\/11772719211035643"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00898"},{"key":"e_1_3_3_143_2","first-page":"83","volume-title":"Group techniques for program planning: A guide to nominal group and delphi processes","author":"Delbecq A","year":"1975","unstructured":"DelbecqA, Ven de Van A, GustafsonD The delphi technique. In: Delbecq A, Ven de Van A, Gustafson D, editors. Group techniques for program planning: A guide to nominal group and delphi processes. Madison: Scott Foresman; 1975, pp. 83\u2013107."},{"key":"e_1_3_3_144_2","article-title":"Expert opinions in forecasting","author":"Rowe G","year":"2001","unstructured":"RoweG, WrightG Expert opinions in forecasting. Role of the delphi technique. In: S AJ, editor. Principles of forecasting: A handbook of researchers and practitioners. Boston: Kluwer Academic Publishers. 2001.","journal-title":"Role of the delphi technique. In: S AJ, editor. Principles of forecasting: A handbook of researchers and practitioners. Boston: Kluwer Academic Publishers"},{"issue":"10","key":"e_1_3_3_145_2","first-page":"1","article-title":"The delphi technique: Making sense of consensus","volume":"12","author":"Hsu CC","year":"2007","unstructured":"HsuCC, SandfordBA The delphi technique: Making sense of consensus. Practical Assessment, Research and Evaluation. 2007;12(10):1\u20138.","journal-title":"Practical Assessment, Research and Evaluation"},{"key":"e_1_3_3_146_2","unstructured":"FDA-NIH Joint Leadership Council. Best (biomarkers endpoints and other tools) resource. 2016."},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018309"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419846058"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09547-y"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215397"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51625"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120380"},{"key":"e_1_3_3_153_2","unstructured":"Cure SMA. Newborn screening for SMA Available from 2022)\u2013https:\/\/www.curesma.org\/newborn-screening-for-sma\/."},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10030075"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000872"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666191210154535"},{"issue":"3","key":"e_1_3_3_157_2","first-page":"318","article-title":"Association of cerebrospinal fluidneurofilament light protein levels with cognition in patients withdementia, motor neuron disease, and movement disorders","volume":"76","author":"Olsson B","year":"2019","unstructured":"OlssonB, PorteliusE, CullenNC, SandeliusA, ZetterbergH, AndreassonU, et al. Association of cerebrospinal fluidneurofilament light protein levels with cognition in patients withdementia, motor neuron disease, and movement disorders. JAMANeurology. 2019;76(3):318\u201325.","journal-title":"JAMANeurology"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1034684"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274565"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00384-x"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02558-9"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14689"},{"issue":"6","key":"e_1_3_3_164_2","first-page":"24","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius A","year":"2018","unstructured":"SandeliusA, ZetterbergH, BlennowK, AdiutoriR, MalaspinaA, LauraM, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology.e518-e. 2018;90(6):24.","journal-title":"Neurology.e518-e"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174152"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51562"},{"key":"e_1_3_3_167_2","article-title":"A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen","author":"Paris A","year":"2022","unstructured":"ParisA, BoraP, ParoloS, MacCannellD, MonineM, van der MunnikN, et al. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen. CPT: Pharmacometrics & Systems Pharmacology. 2022.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2997"},{"key":"e_1_3_3_169_2","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment","author":"Mercuri E","year":"2022","unstructured":"MercuriE, BaranelloG, Boespflug-TanguyO, De WaeleL, GoemansN, KirschnerJ, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2022.","journal-title":"Eur J Neurol"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-1276"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.08.017"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26446"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac174"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2020.1730434"},{"key":"e_1_3_3_175_2","unstructured":"Cure SMA. State of SMA Available from 2022)\u2013https:\/\/www.curesma.org\/wp-content\/uploads\/2022\/06\/9042022_State-of-SMA_vweb.pdf."},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324254"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1128"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10050"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.11.012"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2018.11.009"},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d3e308"},{"key":"e_1_3_3_182_2","first-page":"27","article-title":"Neurologic evaluation and ancillary tests","author":"Bertorini T","year":"2008","unstructured":"BertoriniT Neurologic evaluation and ancillary tests. In: Bertorini T, editor. Neuromuscular case studies. Philadelphia, PA: Butterworth-Heinemann. 2008), 27\u201376.","journal-title":"In: Bertorini T, editor. Neuromuscular case studies. Philadelphia, PA: Butterworth-Heinemann"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749eca"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JND-230054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JND-230054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:44:30Z","timestamp":1769514270000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JND-230054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":182,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9,8]]}},"alternative-id":["10.3233\/JND-230054"],"URL":"https:\/\/doi.org\/10.3233\/jnd-230054","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}